Administration of weekly doses of DEC205-HEL and DCIR2-HEL fusion proteins, beginning after disease onset (P25), arrested any further development of inflammation (p=0.0061 for DEC205-HEL vs PBS at P60; p=0.0141 for DCIR2-HEL vs PBS at P60) but was only minimally effective in preventing progressive development of chorioretinal atrophy (p=0.0128 for DEC205-HEL vs PBS at P60; p=0.0042 for DCIR2-HEL vs PBS at P60) (Figure 3). The gene discussed is LY75; the disease is Chorioretinal atrophy.